Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) - PROMESA

Klinikum der Universität München, Campus Großhadern0 sites92 target enrollmentJanuary 3, 2014

Overview

please also see abstract of the original paper by Levin et al, Lancet Neurology 2019

Registry

who.int

Start Date

January 3, 2014

End Date

September 16, 2016

Last Updated

last year

Study Type

Interventional

Sex

All

Sponsor

Klinikum der Universität München, Campus Großhadern

•Subjects can be included if they meet the following criteria:
•1\.„clinical possible or „clinical probable MSA (Gilman et al., Neurology, 2008 26;71:670\-6\)
•2\.Hoehn \& Yahr stage I – III
•3\.A stable regimen for at least 1 month prior to V1 and willingness / no fore\-seeable need to change the regimen throughout the 52 week follow\-up pe\-riod for
•a.drugs acting against Parkinsonism (e.g. Levodopa, Dopamine\-Agonists, Amantadine and MAO\-B\-Inhibitors)
•b.drugs acting against autonomic dysfunction (e.g. ephedrin, midodrin, fludrucortison, octreotide, desmopresin, oxybutinine)
•c.antidepressant and antidementive drugs.
•4\.No regular consumption of EGCG, green tea, or more than two cups of black tea per day
•5\.Capability and willingness to give written informed consent indicating that the subject has been informed of and understood all aspects pertinent to the study
•6\.Capability and willingness to comply with the procedures of the study

•Subjects will not be included if any of the following criteria applies:
•1\.Hoehn \& Yahr stage \> III (loss of postural reflexes, no independent walking possible, inability to stand unassisted, wheelchair\-bound).
•2\.Neurodegenerative diseases other than MSA
•3\.Severe liver disease with elevation of transaminases and bilirubin above 2\-folds of the upper normal level or regular intake of hepatotoxic drugs
•4\.Known hypersensitivity to EGCG or to drugs with similar chemical structure
•5\.Participation in another clinical trial involving administration of an investiga\-tional medicinal product within 1 month prior to V1
•6\.A physical or psychiatric condition, which at the investigator’s discretion may put the subject at risk, may confound the trial results, or may interfere with the subject’s participation in this clinical trial
•7\.Persistent abuse of medication, drugs or alcohol
•8\.Consumption of \> 500 ml grapefruit juice per day (leading to inhibition of cytochrome P\-450 isoenzyme 3A4, which may be involved in degradation of EGCG).
•9\.Current or planned pregnancy or breast feeding in females